Radovan Vrḫovac
A5067261991- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Fungal Infections and Studies
- Antifungal resistance and susceptibility
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Blood disorders and treatments
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Mycobacterium research and diagnosis
- Viral-associated cancers and disorders
- Oral health in cancer treatment
- Nutrition and Health in Aging
- Immune Cell Function and Interaction
- Mesenchymal stem cell research
- Histone Deacetylase Inhibitors Research
- Retinoids in leukemia and cellular processes
- Renal Transplantation Outcomes and Treatments
- Transplantation: Methods and Outcomes
University Hospital Centre Zagreb
2016-2025
University of Zagreb
2013-2024
Örebro University Hospital
2023
Amsterdam University Medical Centers
2020
Erasmus University Rotterdam
2020
Erasmus MC
2020
Istanbul University
2020
University of Rome Tor Vergata
2020
École des Hautes Études en Santé Publique
2020
Université Paris-Saclay
2020
Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade lymphoma mantle cell lymphoma. Products other diseases such as multiple myeloma follicular are likely to be by the European Medicines Agency near future.The Society Blood Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT EBMT (JACIE) Haematology Association...
This intercontinental study aimed to gram-negative rod (GNR) resistance in hematopoietic stem cell transplantation (HSCT).GNR bacteremias occurring during 6 months post-HSCT (February 2014-May 2015) were prospectively collected, and analyzed for rates risk factors fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), carbapenems, multidrug resistance.Sixty-five HSCT centers from 25 countries Europe, Australia, Asia reported data on 655 GNR episodes 704 pathogens 591...
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated 551 who received HSCT without ( n = 274) or 277) pretreatment. The overall leukocyte engraftment day 45 was 92% and significantly higher responsive than those had no lost response (94% vs. 85%, p 0.05). 1-year non-relapse mortality 22% significant difference...
Abstract The role of spleen size and splenectomy for the prediction post‐allogeneic hematopoietic stem cell transplant (allo‐HCT) outcome in myelofibrosis remains under debate. In EBMT registry, we identified a cohort 1195 patients transplanted between 2000‐2017 after either fludarabine‐busulfan or fludarabine‐melphalan regimens. Overall, was performed 202 (16.9%) its use decreased over time (28.3% 2000‐2009 vs 14.1% 2010‐2017 period). By multivariate analysis, associated with less NRM (HR...
Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy maribavir with fewer treatment-limiting toxicities than valganciclovir.
QuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy. We evaluated the impact of allo-HCT performed first complete remission (CR1) composite CR1 (CRc1) on overall survival (OS), considering treatment randomization....
Methotrexate is known to synergize with cytarabine [1-beta-D-arabinofuranosylcytosine (ara-C)] in a schedule-dependent manner. The purpose of this article compare and contrast the activity pralatrexate (10-propargyl-10-deazaminopterin)/gemcitabine standard combination methotrexate/ara-C determine if schedule dependency important lymphoma.Cytotoxicity assays using trypan blue exclusion assay were used explore vitro gemcitabine against panel lymphoma cell lines. Both severe combined...
Ruxolitinib (INCB018424) is the first potent, selective, oral inhibitor of JAK1 and 2 being developed for clinical use. Its major cellular systemic effects are proliferation inhibition, apoptosis induction reduction in cytokine plasma levels, all mediated by drug's inhibition JAKs' ability to phosphorylate STAT. In initial trials its use myelofibrosis, ruxolitinib exhibited durable efficacy splenomegaly alleviation constitutional symptoms. Patients also showed weight gain improvement general...
The World Health Organization (WHO)'s Research and Development (R&D) Blueprint for Action to Prevent Epidemics, a plan of action, highlighted several infectious diseases as crucial targets prevention. These infections were selected based on thorough assessment factors such transmissibility, infectivity, severity, evolutionary potential. In line with this blueprint, the VACCELERATE Site Network approached disease experts rank listed in WHO R&D according their perceived risk triggering...
Introduction Chronic graft-versus-host disease (cGvHD) is a serious late complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods This multicenter analysis determined the cumulative incidence (CI) cGvHD and acute GvHD (laGvHD) its impact on transplantation-related mortality (TRM), relapse (R), overall survival (OS) in 317 patients [296 adults, 21 pediatrics (<12 years age)] who underwent their first allo-HSCT 2017. Results The CI laGvHD was 10.5% adults...